KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Arbutus Biopharma (ABUS) over the last 17 years, with Q3 2025 value amounting to $97.7 million.

  • Arbutus Biopharma's Liabilities and Shareholders Equity fell 3042.63% to $97.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $449.7 million, marking a year-over-year decrease of 2444.34%. This contributed to the annual value of $131.7 million for FY2024, which is 879.08% down from last year.
  • Arbutus Biopharma's Liabilities and Shareholders Equity amounted to $97.7 million in Q3 2025, which was down 3042.63% from $103.3 million recorded in Q2 2025.
  • In the past 5 years, Arbutus Biopharma's Liabilities and Shareholders Equity registered a high of $236.9 million during Q1 2022, and its lowest value of $97.7 million during Q3 2025.
  • Its 5-year average for Liabilities and Shareholders Equity is $161.9 million, with a median of $158.6 million in 2023.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first soared by 6197.83% in 2022, then crashed by 3547.55% in 2025.
  • Quarter analysis of 5 years shows Arbutus Biopharma's Liabilities and Shareholders Equity stood at $204.5 million in 2021, then dropped by 4.43% to $195.4 million in 2022, then decreased by 26.11% to $144.4 million in 2023, then decreased by 8.79% to $131.7 million in 2024, then decreased by 25.81% to $97.7 million in 2025.
  • Its Liabilities and Shareholders Equity stands at $97.7 million for Q3 2025, versus $103.3 million for Q2 2025 and $117.0 million for Q1 2025.